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Nonsense-mediated mRNA decay (NMD) is an
important mRNA surveillance system, and human
PNRC2 protein mediates the link between mRNA
surveillance and decapping. However, the mecha-
nism by which PNRC2 interacts with the mRNA
surveillance machinery and stimulates NMD is
unknown. Here, we present the crystal structure of
Dcp1a in complex with PNRC2. The proline-rich
region of PNRC2 is bound to the EVH1 domain of
Dcp1a, while its NR-box mediates the interaction
with the hyperphosphorylated Upf1. The mode of
PNRC2 interaction with Dcp1a is distinct from those
observed in other EVH1/proline-rich ligands interac-
tions. Disruption of the interaction of PNRC2 with
Dcp1a abolishes its P-body localization and ability
to promote mRNA degradation when tethered to
mRNAs. PNRC2 acts in synergy with Dcp1a to stim-
ulate the decapping activity of Dcp2 by bridging the
interaction between Dcp1a and Dcp2, suggesting
that PNRC2 is a decapping coactivator in addition
to its adaptor role in NMD.
INTRODUCTION
Nonsense-mediated mRNA decay (NMD) is an mRNA surveil-
lance pathway that degrades mRNAs harboring premature
termination codons (PTCs), thereby preventing the expression
of nonfunctional or potentially deleterious truncated proteins in
the cell (Amrani et al., 2006; Behm-Ansmant et al., 2007; Chang
et al., 2007; Isken and Maquat, 2007; Mu¨hlemann et al., 2008;
Rebbapragada and Lykke-Andersen, 2009). In addition to its
role in mRNA surveillance, NMD also regulates the stability of
a subset of normal mRNAs in diverse eukaryotes (He et al.,
2003; Mendell et al., 2004; Rehwinkel et al., 2005; Weischenfeldt
et al., 2008; Wittmann et al., 2006).Structure 20, 2025–20In yeast, the mechanism by which a PTC is discriminated
from a normal stop codon is influenced both by whether the
terminating ribosome interacts with the poly(A)-binding protein
(PAB1) at the 30-UTR (Amrani et al., 2006; Mu¨hlemann et al.,
2008; Rebbapragada and Lykke-Andersen, 2009) and by other
features of the termination context as there is an evidence
showing that NMDdoes not require PAB1 or a poly(A) tail (Meaux
et al., 2008). In mammalian cells, recognition of PTCs result from
the crosstalk between terminating ribosomes and a downstream
cis-acting signal known as exon junction complex (EJC), which
can include Upf2 and Upf3 (Chang et al., 2007; Isken and Ma-
quat, 2007). If a ribosome encounters a PTC during translation
of an erroneous mRNA, it is thought to stall, leading to the forma-
tion of a SURF complex, which consists of the SMG1 kinase,
Upf1, and two polypeptide release factors eRF1 and eRF3 (Ka-
shima et al., 2006). Subsequently, the interaction of the SURF
complex with EJC triggers Upf1 phosphorylation (Kashima
et al., 2006) and the decay of the aberrant mRNA is initiated
by decapping, deadenylation, and/or endonucleolytic cleavage
(Mu¨hlemann and Lykke-Andersen, 2010).
Decapping is a key step in both general (Coller and Parker,
2004; Franks and Lykke-Andersen, 2008) and a number of
specialized 50-to-30 mRNAdecay pathways, including NMD (Am-
rani et al., 2006; Lejeune et al., 2003), AU-rich element (ARE)-
mediated decay (Fenger-Grøn et al., 2005), miRNA-mediated
decay (Behm-Ansmant et al., 2006; Eulalio et al., 2007; Song
andKiledjian, 2007), and 30 uridylation-mediated decay (Rissland
and Norbury, 2009; Song and Kiledjian, 2007).
Removal of the cap structure is catalyzed by the decapping
enzyme complex, which is composed of the catalytic subunit,
Dcp2 and several regulatory proteins acting as both general
and pathway-specific decapping activators (Coller and Parker,
2004; Franks and Lykke-Andersen, 2008; Isken and Maquat,
2007; Parker and Sheth, 2007; Parker and Song, 2004). The
single subunit enzyme Nudt16 was recently shown to be
responsible for decapping of a subset of mRNAs in mammalian
cells (Song et al., 2010). In yeast, the general 50-30 decay requires
the essential activator Dcp1 that directly interacts with Dcp2
and the coactivators, such as Dhh1, the Pat1/Lsm1-7 com-
plex, and the enhancer of decapping proteins Edc1 and Edc237, December 5, 2012 ª2012 Elsevier Ltd All rights reserved 2025
Figure 1. Comparison of Dcp1aEVH1 with EVH1 Domains from
ScDcp1, Mena, Homer, and N-Wasp
(A) Schematic diagrams of domain organization of PNRC2 and hDcp1a. SH3-
binding motif, PRS region and the NR box of PNRC2 are colored in red, pink,
and cyan, respectively, whereas the EVH1 and the trimerization domains are
shown in pale green and yellow.
(B) Structure of Dcp1aEVH1 (pale green) in complex with PNRC2 (pink) with
secondary elements labeled and the N-terminal helix colored in blue.
(C) Structure of ScDcp1 (pale green) with the N-terminal region and the
insertion helices shown in blue and orange, respectively.
(D) Structure of Mena EVH1 domain (lemon) in complex with the FPPPP
peptide from ActA (magenta).
(E) Structure of the Homer EVH1 domain (lemon) in complex with TPPSPF
peptide from mGluR (magenta).
(F) NMR structure of N-Wasp EVH1 (lemon) in complex with WIP peptide
(magenta). Figures 1B–1F and 2 and Figure S1 were produced using PyMOL.
Structure
Structure of Dcp1a-PNRC2(Chowdhury and Tharun, 2009; Coller and Parker, 2004, 2005;
Sheth and Parker, 2006; Teixeira and Parker, 2007), whereas
NMD requires Upf2 and Upf3 to activate decapping (Sheth and
Parker, 2006). In humans, the Dcp1/Dcp2 interaction appears
weaker and for coimmunoprecipitation from cells requires addi-
tional coactivators Edc3, Edc4(Hedls), DDX6/RCK, and TTP in
miRNA- and ARE-mediated mRNA decay pathways (Eulalio
et al., 2007; Fenger-Grøn et al., 2005).
Dcp1 is a small protein containing an EVH1 domain (She
et al., 2004), which is generally a protein-protein interaction
module (Ball et al., 2002) through binding to a proline-rich ligand.
Recently, Borja et al. (2011) showed that the EVH1 domain of
yeast Dcp1 recognizes a novel consensus proline-rich sequence
(PRS) present in Edc1 and Edc2. Upon binding to Dcp1, these
coactivators dramatically stimulate decapping, affecting both
mRNA binding and the rate of the catalytic step. These observa-
tions suggest that a crucial function of Dcp1 is to couple the
binding of the coactivators to substrate recognition and activa-
tion of Dcp2.
The mechanism of how a decapping enzyme is recruited and
activated upon PTC recognition during NMD remains poorly
understood. It has been shown that both yeast and human
Upf1 can coimmunoprecipitate or show two-hybrid interaction
with Dcp1a or Dcp2, but in no case has a direct interaction
been demonstrated (He and Jacobson, 1995, 2001; Lykke-An-
dersen, 2002; Fenger-Grøn et al., 2005; Isken et al., 2008). These
observations suggest that the decapping enzyme is recruited to
the PTC-containing mRNA by Upf1 through either direct or indi-
rect protein-protein interactions. Recently, Cho et al. (2009)
showed that human PNRC2 is a Dcp1a- and Upf1-interacting
protein and interacts preferentially with the hyperphosphory-
lated Upf1, thereby recruiting hyperphosphorylated Upf1 into
cytoplasmic processing bodies (P-bodies). Accordingly, down-
regulation of endogenous PNRC2 abrogates NMD, and artifi-
cially tethering PNRC2 downstream of a normal stop codon
promotes NMD. These results suggest that PNRC2 mediates
the crosstalk between Upf1-containing NMD machinery and
the decapping complex by bridging the interaction between
Dcp1a and Upf1.
PNRC2 is a nuclear receptor coactivator that contains a
proline-rich Src homology domain 3 (SH3)-binding motif and
a short hydrophobic motif LXXLL called the NR-box (Figure 1A)
(Zhou and Chen, 2001; Zhou et al., 2000, 2006). Like its homolog
nuclear receptor coregulatory protein 1 (PNRC1), PNRC2 inter-
acts with many nuclear receptors through its SH3-binding motif
(Zhou and Chen, 2001; Zhou et al., 2000, 2006). Thus, PNRC2
is a bifunctional protein that both regulates transcription and
promotes mRNA decay through NMD. Consistent with these
broad roles, PNRC2 has also been implicated in energy balance
(Zhou et al., 2008), activating aromatase in breast tumors (Raj-
hans et al., 2008) and adipogenesis (Cho et al., 2012). Despite
this importance, how PNRC2 interacts with Upf1 or Dcp1a and
how that interaction can promote decapping have not been
elucidated.
In this study, we determined the crystal structure of the EVH1
domain of human Dcp1a in complex with PNRC2 at a resolu-
tion of 2.6 A˚. The structure shows that the PRS region, including
part of the SH3-binding motif in PNRC2, is bound to the EVH1
domain of Dcp1a by a distinct recognition mechanism. Muta-2026 Structure 20, 2025–2037, December 5, 2012 ª2012 Elsevier Ltdtions disrupting the interaction of PNRC2 with Dcp1a abolished
its P-body localization and the rapid degradation of tethered
mRNA. Isothermal titration calorimetry (ITC) assays show that
the NR-box of PNRC2 mediates the interaction with the hy-
perphosphorylated Upf1. Decapping assays show that eitherAll rights reserved
Structure
Structure of Dcp1a-PNRC2PNRC2 or Dcp1a alone stimulates decapping in vitro and the
Dcp1a/PNRC2 complex synergistically enhanced the decapping
activity of Dcp2. These results reveal the molecular basis of
PNRC2-mediated association between the NMD machinery




The EVH1 domain of human Dcp1a (designated as Dcp1aEVH1)
(residues 1–130; Figure 1A) in complex with human PNRC2 (resi-
dues 1–121, designated as PNRC2DNR) were screened for crys-
tallization conditions and yielded diffraction quality crystals. The
protein complex was crystallized in space group I222, with two
complexes per asymmetric unit (AU). The structure was solved
by single-wavelength anomalous dispersion method at a re-
solution of 2.6 A˚, using data obtained from selenomethionine
(SeMet)-substituted crystal. Residues 1–130 of Dcp1aEVH1
and a stretch of PNRC2 polypeptide chain comprising 14 resi-
dues (residues 102 to 115) are visible in the electron density
map with the rest of the residues in PNRC2 (residues 1–101
and residues 116–121) assumed to be disordered as there is
no interpretable electron density for these regions. The final
model contains two copies of Dcp1aEVH1 (chains A and B) com-
plexed with the PNRC2 peptide (residues 102–115; chains C
and D) with no major differences ( root-mean-square deviation
[rmsd] of 0.30 A˚ for all the equivalent Ca atoms). As chains A
and C are more complete than chains B and D, the subsequent
analysis reported here is based on chains A and C only.
Overall Structure Description
The overall structure of Dcp1aEVH1 (Figure 1B) is similar to that
observed for Saccharomyces cerevisiae Dcp1 (ScDcp1) and for
Mena, Homer, and N-WASP (Figure 1). Structural comparison of
Dcp1aEVH1 with ScDcp1 (She et al., 2004; rmsd of 1.28 A˚
for all equivalent Ca atoms) reveals two notable differences
between these two structures. First, two short helices, which
are located at one of the two species-specific insertions (She
et al., 2004), are present in ScDcp1 but absent in Dcp1aEVH1.
Second, the N-terminal region of ScDcp1 forms a 310-helix
plus an extended polypeptide, whereas in Dcp1aEVH1 this
region is a long a-helix, which is similar to the long N-terminal
a-helix observed in the structure of Schizosaccharomyces
pombe Dcp1 bound to Dcp2 (She et al., 2008). The PNRC2
peptide adopts a largely extended conformation and contacts
a concave groove formed by stands b1, b2, b5, b6, and b7 of
Dcp1aEVH1, which includes the canonical PRS binding site
observed in other EVH1 domains (see below).
The Dcp1aEVH1-PNRC2 Interface
The surface of Dcp1aEVH1 for the PNRC2 peptide binding con-
sists of two hydrophobic pockets with Trp45 and Leu96 bridging
their link (Figure 2A). The first pocket (designated as hydrophobic
pocket 1), which corresponds to patch 1 of ScDcp1 (She et al.,
2004), is made up of the side chains of conserved residues
Tyr36, Trp45, Phe94, Leu96, and Trp108, whereas the second
pocket (designated as hydrophobic pocket 2) is formed by the
side chains of Phe38, Trp45, Leu96, Ile104, and the methyleneStructure 20, 2025–20groups of Glu87, Gln89, and Arg98. The N- and C-terminal
portions of the PNRC2 peptide contact hydrophobic pockets 1
and 2, respectively, whereas its middle portion containing the
sequence LPKP docks at the ridge formed by Trp45 and
Leu96 through multiple Van der Waals (VDW) contacts. The
LPKP motif adopts a polyproline II (PPII) conformation (a left-
handed helix with three residues per turn) as observed in other
EVH1-pepide complexes (Ball et al., 2002; see below). Impor-
tantly, one of these two regions (pocket 1) of Dcp1a that interact
with PNRC2 is the same region of Dcp1 shown in yeast to be
important for decapping and for binding to the decapping acti-
vator, Edc1 (Borja et al., 2011; She et al., 2004), suggesting
that these are conserved interaction sites for a variety of decapp-
ing activators in numerous species (see below).
The interactions of the PNRC2 peptide with Dcp1aEVH are
predominantly hydrophobic in nature, supplemented by VDW
contacts and hydrogen bonding (Figure 2A; Figure S1 available
online). Specifically, beginning from the N-terminal portion of
the PNRC2 peptide, Pro102 forms stacking interactions with
the side chain of Trp108 of Dcp1aEVH1, whereas Ser103 makes
multiple VDW contacts with Tyr36, Phe94, and Trp108 of
Dcp1aEVH1, in addition to the hydrogen bond formed between
its carbonyl oxygen and the hydroxyl group of Tyr36 in
Dcp1aEVH1. In the LPKP motif of the middle portion of the
PNRC2 peptide, Leu107 and P108 protrudes into the hydro-
phobic pocket 1 and makes multiple hydrophobic interactions
and two VDW contacts with residues Tyr36, Trp45, Phe94, and
Ser106 of Dcp1aEVH1. In addition, the carbonyl oxygen of
Pro108 is hydrogen-bonded to the indole nitrogen of Trp45 in
Dcp1aEVH1. P110 in the LPKP motif contacts residues Phe38,
Trp45, Leu96, and Ile104 in hydrophobic pocket 2 through
multiple hydrophobic interactions, whereas Lys109 is exposed
to the solvent region and forms a hydrogen bond with the
carbonyl oxygen of Asn43. In the C-terminal portion of the
PNRC2 peptide, the key residue that interacts with Dcp1aEVH1
is Trp114. This residue inserts its side chains deeply in hydro-
phobic pocket 2 and makes hydrophobic interactions with the
side chains of Leu96 and Ile104 as well as the methylene groups
of Glu87 and Arg98. In addition, the indole nitrogen of Trp114 is
hydrogen-bonded to the OE1 atom of Glu87. Most of the resi-
dues involved in the Dcp1aEVH1-PNRC2 interface are highly
conserved, therefore underlining their important roles in the
interaction between Dcp1a and PNRC2 (Figures S2 and S3).
PNRC2 Recognition by Dcp1aEVH1
Several lines of evidence suggest that the PNRC2 peptide may
bind to Dcp1aEVH via a novel recognition mechanism. First,
the PNRC2 peptide does not share common motifs with the
PRS ligands in other EVH1 domains, and its length (14 residues)
is more than twice as long as the minimal PRS peptide (six
residues) sufficient for Mena or Homer EVH1 recognition but
is shorter than the Wasp Inhibitor Peptide (WIP; 25 residues)
that binds to N-Wasp EVH1 (Ball et al., 2002). Third, in the struc-
ture of Dcp1aEVH1 complexed with the PNRC2 peptide, the
buried surface (1,450 A˚2) is more than twice that of Mena
(Prehoda et al., 1999; 710 A˚2) or Homer (Beneken et al.,
2000; 560 A˚2) in complex with its respective PRS peptide but
is smaller than that of the N-Wasp EVH1 with boundWIP peptide
(Volkman et al., 2002; 2,130 A˚2). Fourth, as shown in Figure 2,37, December 5, 2012 ª2012 Elsevier Ltd All rights reserved 2027
Figure 2. Surface Views of the Interfaces between the EVH1
Domains and Their PRS Ligands
Residues involved in the interfaces are labeled and shown as stickmodels. The
surface utilized by the EVH1 domain for recognizing the PRS ligand is shown in




2028 Structure 20, 2025–2037, December 5, 2012 ª2012 Elsevier Ltda set of four aromatic residues (Tyr36, Phe38, Trp45, and Phe94)
in Dcp1aEVH1 is involved in the recognition of the PNRC2 PRS
peptide. In contrast, a different set of three aromatic residues
in other EVH1 domains (Tyr16, Trp23, and Phe77 in Mena;
Phe14, Trp24, and Phe74 in Homer and Tyr46; and Trp54 and
Phe104 in N-Wasp) is responsible for recognizing the PRS
ligands.
Although the binding of PNRC2 to Dcp1aEVH1 retains the
characteristics that are common to all classes of previously char-
acterized EVH1 domains upon binding to their respective PRS
peptides (Figure 2), that is, the proline-rich motif of PNRC2,
LPKP, binds to the same canonical aromatic surface utilized by
all classes of EVH1 domain to recognize their peptide ligands
and adopts a polyproline II (PPII) helical conformation, several
features indicated that the interaction between Dcp1aEVH1
and PNRC2 appears to encompass the elements that were
previously thought to be unique to all three classes of EVH1
domain. First, the binding of the LPKP motif of the PNRC2
peptide to Dcp1aEVH1 resembles that of the FPPPP peptide
bound to the Mena EVH1 (Prehoda et al., 1999). Moreover, the
stacking interaction between the methylene group of Arg98 in
Dcp1a and Trp114 in the C-terminal portion of the PNRC2
peptide (Figure 2A; Figure S1) is similar to the interaction
between Arg81 of Mena and Phe1 of the FPPPPT peptide (Fig-
ure 2B). Second, the N-terminal portion of the PNRC2 peptide
binds to the edge of the hydrophobic pocket 1 of Dcp1aEVH1
in a conformation similar to that observed for the mGlu peptide
bound to theHomer EVH1 domain (Beneken et al., 2000) (Figures
2A and 2C). Third, the PNRC2 peptide binds to Dcp1aEVH1 in
the same orientation as the WIP peptide bound to the N-Wasp
EVH1 but in a reverse orientation as compared to the PRS
ligands bound to Mena and Homer (Volkman et al., 2002) (Fig-
ure 1). Taken together, these results indicate that Dcp1aEVH1
recognizes PNRC2 via a distinct recognition mechanism.
Mutational Effects on the PNRC2/Dcp1a Interaction,
P-Body Localization and NMD
To delineate the role of the interface between Dcp1aEVH1
and PNRC2 in vivo, we mutated residues in the Dcp1aEVH1/
PNRC2 interface and examined the effects of these mutations
on their interactions as well as on P-body localization and the
ability of PNRC2 to stimulate mRNA degradation. Yeast two-
hybrid assays identified one mutation L96A in Dcp1a that
abolished the binding to PNRC2 and four Dcp1a mutations
Y36A, W45A, F94A, and R98A that showed reduced binding
to PNRC2 (Figure 3A). Moreover, in PNRC2 the mutations
W114A and K109A abrogated the binding of PNRC2 to Dcp1a,
whereas mutation P108A substantially reduced binding to(A) Surface representation ofDcp1aEVH1withboundPNRC2peptide (residues
102–115). The LPKP motif of PNRC2 in a PPII conformation docks against the
conserved aromatic surface spanning from hydrophobic pocket 1 to 2.
(B) Surface representation of the Mena EVH1 domain in complex with the
FPPPP peptide.
(C) Surface representation of the Homer EVH1 domain in complex with the
TPPSPF peptide.
(D) Surface representation of the N-Wasp EVH1 domain with the bound WIP
peptide.
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Structure
Structure of Dcp1a-PNRC2Dcp1a (Figure 3B). Consistent with these results, coimmunopre-
cipitation assays showed that PNRC2 mutants (PNRC2 W114A,
and PNRC2 P108A) fail to or very weakly interact with Dcp1a,
compared to PNRC2 WT (Figure 3C).
These mutations suggest that PNRC2 and other coactivators
bind Dcp1/Dcp1a in a similar manner. For example, the mutation
of Tyr47 to alanine in ScDcp1 (equivalent to Tyr36 in Dcp1a) dis-
rupted its binding to the Edc1 PRS peptide (Borja et al., 2011).
Moreover, and analogous to the Pro118 and Trp114 mutations
in PNRC2, the corresponding residues in yeast Edc1 (Pro170)
(Borja et al., 2011) and SMAD4 (Trp302) (Bai et al., 2002) have
been found to be essential for binding to ScDcp1 and Dcp1a,
respectively.
To check whether mutations of P108A and W114A in
PNRC2 affect its P-body localization, the endogenous Dcp1a
was used as a P-body marker. As shown in Figures 3D and
3E, the signal from wild-type (WT) PNRC2 almost completely
overlapped with that from Dcp1a, indicating PNRC2 is local-
ized to P-bodies. On the other hand, PNRC2(W114A), which
disrupts the interaction with Dcp1a, was mainly localized to
nucleus, whereas PNRC2(P108A), with reduced Dcp1a interac-
tion, was localized to both P-bodies and nucleus. Thus, the inter-
action of PNRC2 with Dcp1a is required for its localization to
P-bodies.
To test if the interaction of PNRC2with Dcp1a is required for its
ability to promote mRNA degradation, we examined how the
P108A and W114A mutations in PNRC2 affected its ability to
promote mRNA degradation when tethered to mRNAs through
the MS2 RNA binding proteins (Cho et al., 2009). As assessed
by quantitative real-time RT-PCR, we observed that tethering
of PNRC2(WT) strongly reduced mRNA levels, tethering of
W114A and P108Amutations into PNRC2 inhibited the efficiency
of mRNA degradation by 6.4- and 2.5-fold, respectively (Figures
3F and 3G). Taken together, these results indicate that the bind-
ing of PNRC2 to Dcp1a is important for its P-body localization
and for PNRC20s ability to promote mRNA degradation.
The NR Box of PNRC2 Is Required for Binding to the
Phosphorylated Upf1
Yeast two-hybrid showed that the SH3-binding motif and/or the
NR box in the C terminus of PNRC2 is sufficient for Upf1 bindingFigure 3. Mutational Effects on the PNRC2/Dcp1a Interaction, P-Body
(A and B) Yeast two-hybrid analysis of the interaction between Dcp1a and PNR
PNRC2 in BD vector. (B) Wild-type and five interface mutants of PNRC2 in BD vec
proteins were first selected on auxotrophic media lacking leucine, tryptophan (DD
and tryptophan but containing 120 ng/ml aureobasidin A (TDO AbA+ panel).
(C) IPs of PNRC2WT and its variants. HEK293T cells were transiently transfected
PNRC2 P108A. Two days later, cell lysates were treated with RNase A, and then
Dcp1awas normalized to the level of immunoprecipitatedMyc-PNRC2WT,W114
to one.
(D) Immunostaining of PNRC2 WT and its deletion variants. HeLa cells were tra
PNRC2 (W114A), or Myc-PNRC2 (P108A). Cells were stained with a-Myc antibody
boxed areas are shown in the upper left corner of each image.
(E) The levels of colocalization shown in (D) were determined by Pearson’s corre
ments. Two-tailed, equal-sample variance Student’s t tests were used to calcula
(F and G) Tethering of PNRC2WT and its deletion variants. HeLa cells were transie
plasmid expressing MS2-fused tethering protein, and the reference plasmid expre
MS2 fusion proteins. (G) qRT-PCR of b-6bsmRNA andMUPmRNA. The levels of b
of b-6bs mRNA in the presence of MS2-HA were set to 100%. The columns and b
three independent transfections and qRT-PCRs. *p < 0.05.
2030 Structure 20, 2025–2037, December 5, 2012 ª2012 Elsevier Ltdand PNRC2 preferentially interacts with hyperphosphorylated
Upf1 compared with wild-type Upf1 (Cho et al., 2009). Preferen-
tial association between hyperphosphorylated Upf1 and Dcp1a
also has been reported (Isken et al., 2008), but indirect interac-
tion cannot be ruled out as the binding result was obtained using
coimmunoprecipitation. Our structure shows that the PRS region
downstream of the SH3-binding motif in PNRC2 directly binds to
Dcp1a, whereas Zhou et al. (2006) showed that the SH3-binding
motif is essential for binding to the nuclear receptors. Thus, the
binding of Upf1 to Dcp1a might be mediated by the direct asso-
ciation of the hyperphosphorylated Upf1 with the NR box of
PNRC2.
To examine if the NR box of PNRC2 directly binds to the
hyperphosphorylated Upf1, we synthesized a double-phosphor-
ylated Upf1 peptide L(pS)QPEL(pS)QDSYLGD, which is derived
from the human Upf1 C-terminal SQ-containing peptide LSQP
ELSQDSYLGD. This peptide has been shown to be the best
substrate phosphorylated by human SMG1 (Yamashita et al.,
2001). ITC titration was used to analyze the binding of this
double-phosphorylated Upf1 peptide to the protein complexes
Dcp1aEVH1-PNRC2DNR and Dcp1aEVH1-PNRC2FL (herein
the full-length PNRC2 was used). As a control, the binding of the
nonphosphoryated Upf1 peptide to Dcp1aEVH1-PNRC2FL was
also examined. Dcp1aEVH1-PNRC2FL binds to the double-
phosphorylated Upf1 peptide with an apparent Kd of 0.21 mM
(Figure 4A) and shows no binding to the nonphosphoryated
Upf1 peptide (Figure 4B), whereas Dcp1aEVH1-PNRC2DNR in
which the NR-box of PNRC2 was deleted shows no detectable
binding to the phopho-Upf1 peptide (Figure 4C). Taken together,
these results suggest that the NRbox of PNRC2 is required for its
binding to the phosphorylated Upf1.
PNRC2 and Dcp1a Synergistically Stimulate Decapping
In Vitro
The C-terminal regions of Edc1 and Edc2 contain a proline-rich
consensus sequence that binds to ScDcp1, thereby allowing
ScDcp1 to recruit the coactivators Edc1 and Edc2 to Dcp2
for decapping stimulation (Borja et al., 2011; Schwartz et al.,
2003). Sequence comparison showed that the PNRC2 pep-
tide bound to Dcp1aEVH1 shares the characteristic of the
proline-rich consensus sequence of Edc1 and Edc2 (Figure 5A),Localization, and Degradation of the Tethered mRNA
C2. (A) Wild-type and seven interface mutants of Dcp1a in AD vector against
tor against Dcp1a in AD vector. The cotransformed yeast cells expressing both
O panel), and replica-plated on highly selectivemedia lacking histidine, leucine,
with plasmids expressingMyc, Myc-PNRC2WT, Myc-PNRC2W114A, or Myc-
IPs were performed using a-Myc antibody. The level of coimmunoprecipitated
A, or P108A. The normalized level in the IP presence ofMyc-PNRC2WTwas set
nsiently transfected with plasmids expressing either Myc-PNRC2 (WT), Myc-
and a-Dcp1a antibody. Nuclei were stained with DAPI. Enlarged images of the
lation coefficient. At least ten cells were analyzed in two independent experi-
te the p values. **p < 0.01.
ntly cotransfected with the reporter plasmid expressing b-6bs mRNA, effector
ssing MUPmRNA. (F) Western blotting to show the comparable expression of
-6bs mRNAwere normalized to the level of MUPmRNA. The normalized levels
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Structure
Structure of Dcp1a-PNRC2suggesting that PNRC2 may stimulate the decapping itself
through Dcp1a-mediated recruitment to Dcp2.
Because ScDcp1 just contains the EVH1 domain, yet is
capable of stimulating decapping in vitro (She et al., 2004,
2006; Sheth and Parker, 2006), we reasoned that the EVH1
domain alone of human Dcp1a might be sufficient to stimulate
decapping in vitro. As expressing Dcp1aEVH1 or PNRC2DNR
alone in Escherichia coli gave rise to insoluble protein, we
coexpressed Dcp1aEVH1 and PNRC2DNR(W114A), a mutant
showing residual binding to Dcp1aEVH1 (Figure 3B, see above).
The residual interaction between Dcp1a and PNRC2DNR
(W114A) improved the solubility of each individual protein and
allowed us to purify Dcp1aEVH1 and PNRC2DNR(W114A)
separately by attaching a His-tag to either Dcp1aEVH1 or
PNRC2DNR(W114A) in two separate coexpression constructs
and then removing the untagged protein by washes of the Ni-
affinity column. SDS-PAGE gel showed that purified Dcp1aEVH1
and PNRC2DNR(W114A) are at least 95% pure (Figure S4).
Decapping assays showed that Dcp1aEVH1 alone stimu-
lated decapping moderately (Figure 5B, lanes 5–7; Figure 5C,
lanes 5–7), whereas PNRC2DNR(W114A) alone stimulated de-
capping strongly (Figure 5B, lanes 8–10; Figure 5C, lanes 8–10).
The stronger decapping stimulation of PNRC2DNR(W114A)
could be contributed to some extent by the trace amount
of Dcp1aEVH1 that copurified with this mutant. When the
Dcp1aEVH1-PNRC2DNR complex was added to the decapping
reaction solution, the efficiency of decapping activity of human
Dcp2wasmarkedlyenhanced (Figure5B, lanes11–13;Figure5C,
lanes 11–13), suggesting that PNRC2 andDcp1aEVH1worked in
a cooperative manner to stimulate Dcp2 decapping activity.
To gain insight into the mechanism by which PNRC2 stimu-
lates decapping, we examined whether GST-Dcp2 binds to
purified Dcp1aEVH1, PNRC2DNR(W114A), and their complex
by His-tag pull-down assays. Western blotting analysis using
a-GST antibody showed that the complex bound to GST-Dcp2
strongly, and PNRC2DNR(W114A) bound to GST-Dcp2 weakly,
whereas Dcp1aEVH1 had no detectable binding to GST-Dcp2
(Figure 6A). The interaction of the complex or PNRC2DNR
(W114A) with GST-Dcp2 is not mediated by GST as GST alone
had no interaction with the proteins used here (Figure 6A).
Consistent with the in vitro binding results, downregulation of
endogenous PNRC2 using small interfering RNA (siRNA) (Fig-
ure 6B) reduced the interaction between endogenous Dcp1a
and FLAG-Dcp2 by about 3-fold (Figure 6C), suggesting that
PNRC2 plays a role in mediating the association between
Dcp1a and Dcp2. Taken together, these results indicate that
PNRC2 is a bona fide decapping coactivator and acts synergis-
tically with Dcp1a to activate decapping in addition to its adaptor
role in NMD.
DISCUSSION
In this study, we have shown that the PNRC2 peptide binds to
Dcp1aEVH1 via a distinct recognition mechanism. Interestingly,Figure 4. The NR Box of PNRC2 Is Required for Binding to the Phosph
(A and B) ITC titrations of the double-phosphorylated and nonphosphorylated Up
(C) Titration of the double-phosphorylated Upf1 peptide to the Dcp1aEVH1-PNRC
panels show the integrated heat for each injection fitted to a single-site model.
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the Dcp1aEVH1 surface outside the canonical PRS binding
groove with the side chains of the proline residues (Pro102 and
Pro104) exposed to the solvent region (Figure 2A), suggesting
that this motif does not contribute much to the binding specificity
toward Dcp1a. Consistent with this observation, the SH3 binding
motif of PNRC2 has been shown to be essential for its interaction
with the nuclear receptors (Zhou et al., 2006). The LPKP motif of
the PNRC2 peptide binds to the canonical PRS binding site and
adopts a PPII conformation with Pro108 being one of the key
specificity determinants (Figures 2A and 3B). In the C-terminal
portion of the PNRC2 peptide, Trp114, a second critical residue
for binding specificity, protrudes deeply into a hydrophobic
pocket on the Dcp1a surface (Figure 2A). Consistent with these
observations, point mutations of these two residues in PNRC2
showed strong defects in Dcp1a binding, P-body localization,
and degradation of tethered mRNAs (Figure 3).
Our decapping assays show that both Dcp1aEVH1 and
PNRC2 in isolation simulate decapping and, more importantly,
that PNRC2 works in synergy with Dcp1a to promote the
decapping activity of Dcp2 (Figures 5B and 5C). In yeast,
Edc1 and Edc2 stimulate decapping through ScDcp1-mediated
recruitment to Dcp2, as Dcp1 and Dcp2 physically interact with
each other to form the holo-decapping enzyme (Beelman et al.,
1996; Sakuno et al., 2004; Steiger et al., 2003). However, in
mammals, the interaction of Dcp1a with Dcp2 has been reported
to be mediated by the adaptor protein Edc4 (Hedls), which itself
is a decapping coactivator (Fenger-Grøn et al., 2005), suggest-
ing that the recruitment of PNRC2 to Dcp2 is not directly medi-
ated by Dcp1a. Consistent with this notion, our pull-down and
western blotting analyses indicate that PNRC2 directly binds to
Dcp2 albeit with low affinity, whereas the binding of Dcp1a to
Dcp2 is mediated by PNRC2 (Figure 6). Therefore, in contrast
to the mode of action of Edc1 and Edc2 (Borja et al., 2011),
PNRC2 stimulates decapping through direct binding to Dcp2,
whereas Dcp1a stimulates decapping through PNRC2-medi-
ated recruitment to Dcp2. Given that Upf1 phosphorylation is
a key step in PTC recognition during NMD and PNRC2 preferen-
tially binds the hyperphosporylated Upf1 (Cho et al., 2009), the
direct interactions of PNRC2 with both Dcp1a and Dcp2 would
link the mRNA surveillance machinery with the decapping com-
plex after Upf1 phosporylation, therefore transducing the signal
of PTC recognition to the decapping complex and triggering
mRNA decapping.
Two recent reports have demonstrated that transcription
factors and DNA promoters can directly influence the relative
stablility of transcripts that they produce (Bregman et al., 2011;
Trcek et al., 2011), suggesting that transcription and mRNA
decay are coordinated to each other to regulate the level of an
mRNA. In further support of these observations, mRNA decapp-
ing factors Dcp1a, Dcp2, and Edc3 and exonuclease Xrn2 were
reported to function in widespread premature termination of
RNA polymerase II transcription (Brannan et al., 2012). Dcp1a
(also called SMIF) has been shown to function as a crucialorylated Upf1 Peptide
f1 peptides to the Dcp1aEVH1-PNRC2FL complex, respectively.
2DNR complex. The upper panels show the binding isotherms, and the lower
All rights reserved
Figure 5. Dcp1a and PNRC2 Synergistically Stimulate the Decapp-
ing Activity of hDcp2
(A) Sequence alignment of the proline-rich region of PNRC2 (residues 102–
115) with the proline-rich sequences of Edc1 (residues 163–175) and Edc2
(residues 134–145) from S. cerevisiae and Smad4 (residues 290–304) from
Homo sapiens.
(B)Upperpanel: EffectsofDcp1aEVH1,PNRC2DNR(W114A), andDcp1aEVH1-
PNRC2DNR on the decapping activity of hDcp2(1–245). The enhanced de-
capping activitieswere quantified using the amount of cap-labeledRNA relative
to that of hDcp2(1–245) alone (lane 4) from three independent measurements
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Structure 20, 2025–20transcriptional coactivator in TGFb signaling (Bai et al., 2002). In
this study, we demonstrate that PNRC2 stimulates mRNA de-
capping. Therefore, both Dcp1a and PNRC2 are bifunctional
proteins to regulate both decapping and transcription by acting
as a decapping activator and a transcriptional coactivator.
Dcp1a binds to the C-terminal proline-rich linker region of
SMAD4 using its EVH1 domain (Bai et al., 2002). A Trp residue
(Trp302) in this proline-rich linker region of SMAD4 is critical for
binding to SMIF and its transcriptional activity. Sequence anal-
ysis shows that the PNRC2 peptide and the proline-rich linker
region of SMAD4 share a consensus sequence with Trp302 in
SMAD4 corresponding to Trp114 in PNRC2 (Figure 5A). The con-
servation of this aromatic residue in the PRS peptide between
PNRC2 and SMAD4 can be extended to Edc1 and Edc2 as
both proteins contain a Phe in the consensus PRS sequence
(Figure 5A). These observations suggest that the presence of
an aromatic residue (Phe or Trp) in the C terminus of the PRS
peptide could be a general feature for binding to the EVH1
domain of Dcp1 proteins. Given that PNRC2, Edc1, and Edc2
stimulate decapping, it would be interesting to investigate in
the future whether SMAD4 is a decapping activator.
EXPERIMENTAL PROCEDURES
Structure Determination
Human PNRC2DNR (residues 1–121) and human Dcp1aEVH1 (residues 1–
130) were coexpressed in E. coli and purified by TALON metal affinity resin,
Mono Q, and Superdex-200 gel filtration columns. Crystals of the Dcp1a/
PNRC2 complex were grown at 15C by hanging drop vapor diffusion method.
Equal volumes of protein and crystallization reagents (27% [w/v] PEG 3350,
0.15 M ammonium acetate, 0.1 M Bis Tris [pH 5.5], and 0.01 M Hexamine
cobalt [III] chloride) were mixed. Before data collection, the crystals were
transferred to the mother liquor containing 15% glycerol and flash frozen in
liquid nitrogen.
Diffraction data were collected at the peak wavelength of selenium absorp-
tion edge (l = 0.9798 A˚) at beamline ID23-1, European Synchrotron Radiation
Facility (ESRF), Grenoble, France. The best diffraction volumes of the crystals
were defined using diffraction cartography (Bowler et al., 2010). The SAD data
were processed using the CCP4 suite (Collaborative Computational Project,
Number 4, 1994). The crystals belong to space group I222 with two molecules
in the asymmetric unit (AU). Six out of seven selenium sites were found by SnB
(Miller et al., 1994). SHARP (de la Fortelle and Bricogne, 1997) was used to
further refine the Se sites and estimate the phase. After solvent flattening,
a partial model built from RESOLVE was used for manual model building
with program COOT (Emsley and Cowtan, 2004). The model was refined
with CNS (Bru¨nger et al., 1998), REFMAC (Murshudov et al., 1997), and Phenix
(Adams et al., 2010) with the use of TLS (Painter and Merritt, 2006a, 2006b).
Water molecules were added using Arp/Warp solvent (Perrakis et al., 2001)with the bars representing standard deviations from the mean. Lower panel:
Quantification of the stimulation effects shown in the upper panel. Student’s t
test was used to assess the statistically significant difference of the decapping
activity of hDcp2(1–245) before (lane 4) and after addition of the indicated
proteins (lanes 7, 10, and 13) with a p value of less than 0.01.
(C) Upper panel: Time-course decapping reactions with the indicated proteins.
The proteins were incubated with cap-labeled RNA at room temperature for
the time points indicated. Lower panel: Quantification of the stimulation effects
shown in the upper panel. Student’s t test was used to assess the statistically
significant difference of the decapping activity of hDcp2(1–245) before (lane 4)
and after addition of the indicated proteins (lanes 7, 10, and 13) with a p value
of less than 0.05. The columns and bars represent the means and standard
deviations, respectively, calculated from three replicate experiments.
See also Figure S4.
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Figure 6. Interactions of PNRC2 and Dcp1a with Dcp2
(A) PNRC2DNR(W114A) and the Dcp1aEVH1-PNRC2DNR complex, but not
Dcp1aEVH1, bind to Dcp2 with weak and strong affinities, respectively. Puri-
fied His-Dcp1aEVH1, His-PNRC2DNR(W114A), and the Dcp1a EVH1-His-
PNRC2DNR complex (toppanel) were separately precipitated with GST-Dcp2
(middle upper panel) or the GST alone (middle lower panel) and analyzed by
western blotting with anti-GST antibody. Coeluted His-tagged proteins were
analyzed by western blotting with anti-His-tag antibody (bottom panel). Note
that His-Dcp1aEVH1 and His-PNRC2DNR(W114A) migrate slower than the
corresponding proteins in the complex probably (first and fourth panels)
because of the presence of His-tag attached to Dcp1aEVH1 and the W114A
mutation in PNRC2DNR, respectively, as the protein identities of the samples
have been confirmed by mass spectrometry analysis.
(B and C) IPs of FLAG-Dcp2 using the extracts of HEK293T cells depleted of
endogenous PNRC2. HEK293T cells were transfected with PNRC2 siRNA or
nonspecific Control siRNA. Two days after transfection, cells were transiently
retransfected with plasmids expressing FLAG-Dcp2. (B) Western blotting of
PNRC2. To demonstrate the quantitativity of western blotting, 3-fold serial
dilutions of total-cell extracts were loaded in the three left-most lanes. (C) IP of
FLAG-Dcp2. IP was performed using a-FLAG antibody or mouse IgG as
a control. The levels of coimmunopurified endogenous Dcp1a were normal-
ized to the level of immunopurified FLAG-Dcp2. The normalized level in
presence of control siRNA was set to one.
See also Figure S4.
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aRmerge = Sjlj h I i j /Slj, where lj is the intensity of an individual reflection,
and h I i is the average intensity of that reflection.
bRcullis = ShjjFPH  FHj  jFHjj/ ShjFPH  FHj.
cRwork = SjjFo  Fcjj/ SjFcj, where Fo denotes the observed structure
factor amplitude, and Fc denotes the structure factor amplitude calcu-
lated from the model.
dRfree is similar to Rwork but calculated with 10.0% of randomly chosen
reflections that are omitted from the refinement.
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2034 Structure 20, 2025–2037, December 5, 2012 ª2012 Elsevier Ltdand further refined by Phenix. The final model has good stereochemistry with
a free R factor of 28.5% and an R factor of 23.4%. Data collection and refine-
ment statistics are shown in Table 1.
Immunostaining
HeLa cells were fixed with 2% paraformaldehyde (Merck, Whitehouse Station,
NJ, USA) in PBS for 10 min and permeabilized with 0.5% Triton X-100 in
PBS for 10 min. The permeabilized cells were incubated in blocking bufferAll rights reserved
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Structure of Dcp1a-PNRC2(1.5% BSA in PBS) for 1 hr and then incubated with either a-Myc antibody
(Calbiochem, Darmstadt, Germany) or a-Dcp1a antibody (Sigma-Aldrich, St.
Louis, MO, USA) for 1 hr. The antibodies were detected with either fluorescein-
or rhodamine-conjugated secondary antibodies (Pierce, Thermo Fisher Scien-
tific Inc., Rockford, IL, USA). Nuclei were stained with DAPI (Biotium, Hayward,
CA, USA). Cells were observed with a ZEISS confocal microscope (LSM510
META). The level of colocalization was quantitated by calculating the Pear-
son’s correlation coefficient with LSM510 META software.
Immunoprecipitation
HEK293T cells were transiently transfected with PNRC2 siRNA (Cho et al.,
2009) or nonspecific control siRNA (Kim et al., 2005) using Oligofectamine
(Invitrogen, Carlsbad, CA, USA). Two days after siRNA transfection, cells
were retransfected with plasmid expressing FLAG-Dcp2 using the calcium
phosphate method. IP was perfomed using indicated antibody as previ-
ously described (Cho et al., 2009). Coimmunopurified proteins were ana-
lyzed by western blotting using the following antibodies: a-FLAG antibody
(Sigma-Aldrich), a-Dcp1a (Cho et al., 2012), a-Myc (Calbiochem), a-b-actin
(Sigma-Aldrich), and a-GAPDH (Ab Frontier, Young In Frontier Co. Ltd, Seoul,
Korea).
Decapping Assays
The preparation of 32P-labeled capped mRNA is described as before (She
et al., 2006). The decapping buffer contains 50mM Tris-HCl (pH 7.9), 30mM
ammonium nitrate and 0.2mMMnCl2. For checking the stimulation of decapp-
ing, 5, 10 and 20 pmol of Dcp1aEVH1 or PNRC2DNR(W114A), and 2, 4 and 6
pmol of the Dcp1aEVH1-PNRC2DNR complex were incubated with 10 pmol of
hDcp2 in the reaction buffer on ice for 1 hr before 80 fmol of the capped RNA
was added. The decapping reaction was carried out at room temperature
before being stopped by addition of 25mMEDTA. Aliquots (5 ml) of the reaction
products from decapping assays was spotted on polyethyleneimine-cellulose
TLC plates (Sigma) and developed in 0.75M LiCl. Quantification of cap-labeled
RNA was performed using a Phosphorimager.
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The coordinates and structure-factor amplitudes of the Dcp1aEVH1-
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